<- Go Home
Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.
Market Cap
EUR 538.8M
Volume
1.8M
Cash and Equivalents
EUR 81.5M
EBITDA
-EUR 192.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
EUR 96.6M
Profit Margin
38.44%
52 Week High
EUR 9.90
52 Week Low
EUR 2.30
Dividend
N/A
Price / Book Value
-4.15
Price / Earnings
-1.56
Price / Tangible Book Value
-3.91
Enterprise Value
EUR 798.2M
Enterprise Value / EBITDA
-4.48
Operating Income
-EUR 199.0M
Return on Equity
591.23%
Return on Assets
-22.77
Cash and Short Term Investments
EUR 232.2M
Debt
EUR 491.6M
Equity
-EUR 129.7M
Revenue
EUR 251.2M
Unlevered FCF
-EUR 140.6M
Sector
Pharmaceuticals
Category
N/A